Cathy Eng
MD, FACP, FASCO
David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program
Vanderbilt-Ingram Cancer Center

Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, VICC Associate Director of Strategic Relations and Research Partnerships, Executive Director of the Young Adults Cancers Program. She was the Ambassador for the American Cancer Society ResearcHERS campaign (2020-2022). She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves on the Professional Development Mentor. She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.

Nationally, Dr. Eng has also been highly active serving on multiple committees for ASCO, ECOG, and SWOG. She was chosen for the ASCO Leadership Development Program, ASCO Social Media Committee, the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee. She has served as the co-chair of the SWOG Rectal/Anal Cancer Subcommittee; the Vice-Chair for the SWOG GI Committee; the Chairman of the NCI Rectal/Anal Task Force, member of the NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee. She participated in the President Biden’s Cancer Moonshot White House Colorectal Cancer Forum.

She has published in many peer-reviewed journals and served on many national grant review panels.

Sessions

Register
General Session

Optimizing Immunotherapy Sequencing in Gastroesophageal Malignancies: Neoadjuvant Chemo–IO vs Perioperative Chemo/RT Followed by Adjuvant Anti–PD-1

Saturday, March 14, 2026
10:25 AM - 11:10 AM
General Session

Advanced Anal Cancer in 2026

Saturday, March 14, 2026
11:10 AM - 11:55 AM
General Session

Is There a Role for Adjuvant HAI Following Liver Resection vs Adjuvant Chemotherapy?: Yes vs No

Saturday, March 14, 2026
2:10 PM - 2:55 PM
General Session

IO Rechallenge in Esophageal and Gastric Cancers: Balancing Safety Concerns vs Potential Benefit of Reinitiation

Sunday, March 15, 2026
10:25 AM - 11:10 AM
General Session

Case-Based Treatment Strategies in Gastrointestinal Cancers

Sunday, March 15, 2026
11:10 AM - 11:55 AM
General Session

Are RAS Inhibitors Ready for Prime Time Use as a Standard of Care in Pancreatic Cancer?: Yes vs No

Sunday, March 15, 2026
2:10 PM - 2:55 PM
General Session

Optimizing Immunotherapy Sequencing in Gastroesophageal Malignancies: Neoadjuvant Chemo–IO vs Perioperative Chemo/RT Followed by Adjuvant Anti–PD-1

Saturday, September 26, 2026
10:05 AM - 10:50 AM
General Session

Advanced Anal Cancer in 2026

Saturday, September 26, 2026
10:50 AM - 11:35 AM
General Session

Is There a Role for Adjuvant HAI Following Liver Resection vs Adjuvant Chemotherapy?: Yes vs No

Saturday, September 26, 2026
1:30 PM - 2:15 PM
General Session

IO Rechallenge in Esophageal and Gastric Cancers: Balancing Safety Concerns vs Potential Benefit of Reinitiation

Sunday, September 27, 2026
10:05 AM - 10:50 AM
General Session

Are RAS Inhibitors Ready for Prime Time Use as a Standard of Care in Pancreatic Cancer?: Yes vs No

Sunday, September 27, 2026
1:30 PM - 2:15 PM
Back to top